A Curious Case of Drug-induced Subacute Cutaneous Lupus Erythematosus

Sir,

Drugs causing drug-induced systemic lupus erythematosus (DI-SLE) are different from drugs causing drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) except for tumor necrosis factor antagonists. Isoniazid is known to cause DI-SLE. However, isoniazid causing DI-SCLE has been infrequently described in the literature.

A 60-year-old female, a known case of tubercular osteomyelitis, presented with multiple erythematous scaly lesions over the body for the last 2 months. The patient was on antitubercular drugs HRZE (isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE) for 2 months and isoniazid, rifampicin, and ethambutol (HRE) for 2 months. The lesions developed after nearly 8 weeks of intake of HRZE. The cutaneous examination showed multiple annular erythematous scaly plaques over the face, trunk, and limbs with accentuation in the photo-exposed sites along with multiple targetoid lesions [Figure 1a and b]. The complete hemogram showed eosinophilia of 11%. The liver function test, renal function test, chest X-ray, 24-hour urine protein, and electrocardiogram (ECG) were within normal limits. Antinuclear antibody (ANA) was positive (1:90, homogenous pattern). The anti Ro/La, antihistone, anti dsDNA, antismith antibodies, and rheumatoid factor were negative. Skin biopsy revealed basal cell vacuolization, colloid bodies, pigment incontinence, infiltration of the vessel wall by inflammatory cells, and karyorrhectic debris [Figure 2a]. The patient was diagnosed as a case of SCLE and started on hydroxychloroquine 300 mg daily along with oral prednisolone 30 mg daily for 2 weeks, topical mometasone, and sunscreen; however, the lesions persisted. Because of the refractory nature of lesions, the drug was suspected as a possible trigger. As isoniazid is more commonly incriminated in systemic lupus erythematosus, isoniazid was stopped and replaced by oral levofloxacin. Rifampicin, ethambutol, and levofloxacin were continued along with levocectizine and topical mometasone, and oral steroids were stopped. After 2 weeks of stopping isoniazid, there was a significant improvement in cutaneous lesions with complete subsidence of lesions at 4 weeks [Figure 2b]. The patient is on follow-up and has not reported any new lesions or systemic symptoms since then.

DI-LE has predominantly systemic symptoms such as fever, arthritis, and serositis, whereas LE-specific skin changes are relatively uncommon. However, in DI-SCLE, there are specific cutaneous lesions and systemic features are minimal or absent. Anti-histone antibodies are frequently present in DI-LE, whereas anti Ro/SSA antibodies are more frequently positive in DI-SCLE.

It is also important to identify and differentiate this subset of patients from idiopathic SCLE (I-SCLE) as removal of the culprit drug is the mainstay of management in DI-SCLE. DI-SCLE usually has an older age of onset than I-SCLE. Latent period between exposure to the drug and the onset of symptoms is 4 to 8 weeks. The disease is more widespread, and involves areas that are usually spared by I-SCLE. Bullous, erythema multiforme-like lesions, purpura, necrotic-ulcerative lesions, malar rash, and the involvement of lower legs are more common in DI-SCLE.

Recently, one case of isoniazid-induced SCLE was described in a HIV-positive female. In our patient, temporal correlation with the intake of drugs, widespread involvement including legs, erythema multiforme-like lesions, and eosinophilia suggested drug as a possible etiology. The patient did not meet the criteria for Rowell syndrome, and SLE was ruled out because of lack of systemic involvement.
The mainstay of treatment is the discontinuation of the culprit drug which leads to the resolution of lesions in a period of nearly 6 to 12 weeks. Other treatment modalities are topical steroids, topical tacrolimus, hydroxychloroquine, and oral steroids.

**Declaration of patient consent**

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given her consent for her images and other clinical information to be reported in the journal. The patient understands that her name and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Callen JP. Drug-induced subacute cutaneous lupus erythematosus—filling the gap in knowledge: Comment on “subacute cutaneous lupus erythematosus induced by chemotherapy”. JAMA Dermatol 2013;149:1075-6.
2. Lowe GC, Henderson CL, Grau RH, Hansen CB, Sontheimer RD. A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol 2011;164:465-72.
3. Marzano AV, Lazzari R, Polloni I, Crosti C, Fabбри P, Cugno M. Drug-induced subacute cutaneous lupus erythematosus: Evidence for differences from its idiopathic counterpart. Br J Dermatol 2011;165:335-41.
4. Guicciardi F, Azzori L, Marzano AV, Tavecchio S, Girolomoni G, Colato C, et al. Are there distinct clinical and pathological features distinguishing idiopathic from drug-induced subacute cutaneous lupus erythematosus? A European retrospective multicenter study. J Am Acad Dermatol 2019;81:403-11.
5. Luwanda LB, Gamell A. Isoniazid-induced subacute cutaneous lupus erythematosus in an HIV-positive woman: A rare side effect to be aware of with the current expansion of isoniazid preventive therapy. Pan Afr Med J. 2018;29:200.
6. Sharma YK, Chauhan S. Overlap syndrome with rowell’s syndrome, antiphospholipid syndrome, primary sterility, and sensorineural hearing loss: A case report, brief review, and analysis of cases of rowell’s syndrome reported from India and Abroad. Indian J Dermatol 2018;63:418-23.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.